GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » EV-to-FCF

Acrux (ASX:ACR) EV-to-FCF : -2.20 (As of Dec. 14, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Acrux EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Acrux's Enterprise Value is A$10.06 Mil. Acrux's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-4.58 Mil. Therefore, Acrux's EV-to-FCF for today is -2.20.

The historical rank and industry rank for Acrux's EV-to-FCF or its related term are showing as below:

ASX:ACR' s EV-to-FCF Range Over the Past 10 Years
Min: -4.4   Med: -0.82   Max: 33.09
Current: -2.2

During the past 13 years, the highest EV-to-FCF of Acrux was 33.09. The lowest was -4.40. And the median was -0.82.

ASX:ACR's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs ASX:ACR: -2.20

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), Acrux's stock price is A$0.032. Acrux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.020. Therefore, Acrux's PE Ratio (TTM) for today is At Loss.


Acrux EV-to-FCF Historical Data

The historical data trend for Acrux's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux EV-to-FCF Chart

Acrux Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.01 -2.07 -1.19 14.08 -4.55

Acrux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 - 14.08 - -4.55

Competitive Comparison of Acrux's EV-to-FCF

For the Biotechnology subindustry, Acrux's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Acrux's EV-to-FCF falls into.



Acrux EV-to-FCF Calculation

Acrux's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.062/-4.579
=-2.20

Acrux's current Enterprise Value is A$10.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acrux's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was A$-4.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux  (ASX:ACR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Acrux's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.032/-0.020
=At Loss

Acrux's share price for today is A$0.032.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Acrux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was A$-0.020.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Acrux EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Acrux's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux Business Description

Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.